白细胞介素28B基因多态性与慢性HBV、HCV感染的相关性

沈文娟; 哈明昊

doi:10.3969/j.issn.1001-5256.2014.10.028

白细胞介素28B基因多态性与慢性HBV、HCV感染的相关性

DOI: 10.3969/j.issn.1001-5256.2014.10.028

上海市第七人民医院感染性疾病科

基金项目:

浦东新区卫生系统学科带头人培养计划立项资助(PWRd2011-06)；上海市浦东新区卫生局卫生科技发展专项基金资助(PW2012A-17)；上海市卫生局科研课题立项资助(20124368)；

详细信息

中图分类号: R512.62;R512.63
计量
- 文章访问数: 2524
- HTML全文浏览量: 17
- PDF下载量: 573
- 被引次数: 0
出版历程
- 收稿日期: 2014-03-21
- 出版日期: 2014-10-20

Research advances in associations between IL28B polymorphisms and chronic hepatitis B /C virus infection

Department of Infectious Diseases, Shanghai Seventh People's Hospital

Research funding:

摘要

摘要: HBV、HCV感染具有慢性化的流行特点。白细胞介素（IL）28B基因多态性与HBV、HCV感染慢性化及干扰素（IFN）抗病毒疗效具有相关性。简述了IL-28B生物学功能及特点,述评了IL-28B基因多态性与HCV感染的相关性,并归纳了目前发现的IL-28B基因多态性与HBV感染的相关性的众多研究报道。分析表明,IL-28B基因多态性与丙型肝炎病程转归及IFN抗病毒疗效的相关性研究报道较为一致;而IL-28B基因多态性与乙型肝炎病程转归,HBV感染后肝硬化、肝癌及IFN抗病毒疗效的相关性研究,各方学者均有不同的见解,尚需进一步的研究。
- 肝炎,乙型 /
- 肝炎,丙型 /
- 白细胞介素类 /
- 多态性,单核苷酸 /
- 综述
Abstract: Chronic infection with hepatitis B/C virus ( HBV/HCV) is a widespread epidemic in China. The single nucleotide polymorphisms ( SNPs) in interleukin 28B ( IL28B) gene have been associated with chronic HBV/HCV infection and response to interferon therapy. The biological functions and characteristics of IL28 B are elaborated on, the associations between HCV infection and IL28 B SNPs are commented on, and current reports of associations between HBV infection and IL28 B SNPs are reviewed. The results support the associations between IL28 B SNPs and disease progression of HCV infection or the curative effect of interferon therapy. However, contradictive results have been obtained in studies of associations between IL28 B SNPs and disease progression of HBV infection, the incidence of liver cirrhosis and primary liver cancer after HBV infection, or the curative effect of interferon therapy, so further investigation is needed.
- hepatitis B /
- hepatitis C /
- interleukins /
- polymorphism, single nucleotide /
- review

HTML全文

参考文献(36)

[1]GANEM D, PRINCE AM.Hepatitis B virus infection--naturat history and clinical consequences[J].N Engl J Med, 2004, 350 (11) :1118-1129.

[2]World Health Organization.Hepatitis B[EB/OL]. (2008-08) [2010-12-09]http//www.who.int/mediacentre/factsheets/fs204/en/.

[3]LIANG X, BI S, YANG W, et al.Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaceination[J].Vaccine, 2009, 27 (47) :6550-6557.

[4]LIANG X, BI S, YANG W, et al.Evaluation of the impact of hepatitis B vaccination among children bom during 1992-2005 in China[J].J Infect Dis, 2009, 200 (1) :39-47.

[5] LU FM, ZHUANG H.Management of hepatifis B in China[J].Chin Med J (Engl) , 2009, 122 (1) :3-4.

[6] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南2010年版[J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.

[7]YANG M, RAO HY.Key points of the AASLD's guidelines on hepatitis C diagnosis and treatment[J].J Clin Hepatol, 2013, 29 (2) :9-14. (in Chinese) 杨明, 饶慧瑛.美国肝病学会丙型肝炎诊治指南要点[J].临床肝胆病杂志, 2013, 29 (2) :9-14.

[8]KETENKO SV, GALLAGHER G, BAURIN VV, et al.IFN-lambads mediate antiviral protection through a distinct class II cytokine receptor complex[J].Nat Immunol, 2003, 4 (1) :69-77.

[9]UZG, MONNERON D.IL-28 and IL-29:newcomers to the interferon family[J].Biochimie, 2007, 89 (6-7) :729-734.

[10]ANK N, WEST H, PALUDAN SR.IFN-lambda:novel antiviral cytokine[J].J Interferon Cytokine Res, 2006, 26 (6) :373-379.

[11]O'BRIEN TR.Interferon-alfa, Interferon-lambda and hepatitis C[J].Nat Genet, 2009, 41 (10) :1048-1050.

[12]IADONATO SP, KAEZE MG.Genomics:Hepatitis C virus gets personal[J].Nature, 2009, 461 (7262) :357-358.

[13]THOMAS DL, THIO CL, MARTIN MP, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature, 2009, 461 (7265) :798-801.

[14]GE D, FELLAY J, THOMPSON AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment—induced viral clearance[J].Nature, 2009, 461 (7262) :399-401.

[15]RAUCH A, KUTALILC Z, DESCOMBES P, et al.Genetic Variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide associationstudy[J].Gastroentemlogy, 2010, 138 (4) :1338-1345.

[16]MANGIA A, THOMPSON A, SANTORO R, et al.An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3patients who do not achieve a rapid virologic response[J].Gastroenterology, 2010, 139 (3) :821-827.

[17]MCCARTHY JJ, LI JH, THOMPSON A, et al.Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin[J].Gastroenterology, 2010, 138 (7) :2307-2314.

[18]REMBECK K, ALSIA, CHRISTENSEN PB, et al.Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3[J].PLoS One, 2012, 7 (1) :e29370.

[19]JACOBSON IM, MCHUTCHISON JG, DUSHEIKO G, et al.Telaprevir for previously untreated chronic hepatitis C virus infection[J].N Engl J Med, 2011, 364 (25) :2405-2416.

[20]HONDA M, SAKAI A, YAMASHITA A, et al.Hepatic ISG exprsssion is associated with genetic variation in interleukin 28B and the outcome of interferon therapy for chronic hepatitis C[J].Gastroenterology, 2010, 139 (2) :499-509.

[21]URBAN TJ, THOMPSON AJ, BRADRICK SS, et al.IL28B genotype is associated with differential expression of intrahepatic interferon, stimulated genes in patients with chronic hepatitis C[J].Hepatology, 2010, 52 (6) :1888-1896.

[22]SAITO H, ITO K, SUGIYAMA M, et al.Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients[J].Hepatol Res, 2012, 42 (10) :958-965.

[23]BOCHUD PY, BIBERT S, KUTALIK Z, et al.IL28B alleles associated with poor Hepatitis C clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes[J].Hepatology, 2012, 55 (2) :384-394.

[24]MARABITA F, AGHEMO A, DE NICOLA S, et al.Genetic variation in the interleukin-28B gene is not associated with fibrosisi progression in patients with chronic hepatitis C and known date of infection[J].Hepatology, 2011, 54 (4) :1127-1134.

[25]AL-QAHTANI AA, AL-ANAZI MR, ABDO AA, et al.Genetic variation in interleukin 28 B and correlation with chronic hepatitis B virus infection in Saudi Arabian patients[J].Liver Int, 2014, 34 (7) :e208-e216.

[26]CHENG L, SUN X, TAN S, et al.Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients[J].Hepatol Res, 2014, 44 (9) :1000-1007.

[27]ZHANG Q, LAPALUS M, ASSELAH T, et al.IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients[J].J Virol Hepat, 2014, 21 (7) :525-532.

[28]CHEN J, WANG L, LI Y, et al.Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese[J].PLoS One, 2012, 7 (12) :e50787.

[29]LEE IC, LIN CH, HUANG YH, et al.IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B[J].PLoS One, 2013, 8 (2) :e58071.

[30]TAMORI A, KAWADA N.HLA classⅡassociated with outcomes of hepatitis B and C infections[J].World J Gastroenterol, 2013, 19 (33) :5395-5401.

[31]KIM SU, SONG KJ, CHANG HY, et al.Association between IL28B Polymorphisms and spontaneous clearance of hepatitis B virus infection[J].PLoS One, 2013, 8 (7) :e69166.

[32]GARCIA-SAMANIEGO J, ROMERO M, GRANADOS R, et al.Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C[J].World J Gastroenterol, 2013, 19 (12) :1943-1952.

[33]LI W, JIANG Y, JIN Q, et al.Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population[J].Liver Int, 2011, 31 (8) :1118-1126.

[34]MARTIN MP, QI Y, GOEDERT JJ, et al.IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection[J].J Infect Dis, 2012, 202 (11) :1749-1753.

[35]LAMPERTICO P, VIGANOM, CHERONI C, et al.IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B[J].Hepatology, 2013, 57 (3) :890-896.

[36]SONNEVELD MJ, WONG VW, WOLTMAN AM, et al.Polymorphisms near IL28B and serologic response to peginterferon in HbeAg positive patients with chronic hepatitis B[J].Gastroenterology, 2012, 142 (2) :513-520.

施引文献

资源附件(0)

访问统计